DUBLIN, Nov. 30, 2023 /PRNewswire/ — The “CNS Therapeutics – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.
Global CNS Therapeutics Market to Reach $199 Billion by 2030
The global market for CNS Therapeutics estimated at US$114.9 Billion in the year 2022, is projected to reach a revised size of US$199 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2022-2030.
The global CNS (Central Nervous System) therapeutics market is witnessing significant growth due to various factors. One key driver is the rising incidence of neurodegenerative conditions, which is becoming more prevalent as the global aging population increases and life expectancy extends. Moreover, increased spending on prescription drugs and rising healthcare expenditure are contributing to the expansion of the CNS therapeutics market. The growing middle-class population in emerging regions is also spurring market growth.
Neurodegenerative Diseases, one of the segments analyzed in the report, is projected to record 7.7% CAGR and reach US$75.9 Billion by the end of the analysis period. Growth in the Mental Health segment is estimated at 6.9% CAGR for the next 8-year period.
In addition to these demographic and economic factors, advancements in CNS drug delivery technologies are positively impacting the market. Understanding the biology of the blood-brain barrier (BBB) is opening new possibilities, as seen in the case of epilepsy drugs. Pharmaceutical companies are actively seeking new tools to offset pressure on their drug pipelines and launching awareness campaigns to benefit the market.
Furthermore, innovative approaches such as music and memory programs are positively impacting patients with Alzheimer’s disease and related dementia. Additionally, there is ongoing research on psychedelic substances, paving the way for timely treatment of various mental illnesses.
The advent of advanced disease pathology and diagnostic techniques is facilitating earlier-stage diagnosis of mental illnesses, further fueling the demand for biological medicines in the CNS therapeutics market. Despite the complexities of research and development in this field, the future outlook for CNS therapeutics appears promising, with novel drug-delivery options and advances in drug discovery methods for rare diseases.
The U.S. Market is Estimated at $46.5 Billion, While China is Forecast to Grow at 11% CAGR
The CNS Therapeutics market in the U.S. is estimated at US$46.5 Billion in the year 2022. China, the world’s second largest economy, is forecast to reach a projected market size of US$19.9 Billion by the year 2030 trailing a CAGR of 11% over the analysis period 2022 to 2030.
Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.5% and 6.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.
What’s New?
Special discussions on the global economic climate and market sentiment
Coverage on global competitiveness and key competitor percentage market shares
Market presence analysis across multiple geographies – Strong/Active/Niche/Trivial
Online interactive peer-to-peer collaborative bespoke updates
Access to digital archives and trademarked research platform
Complimentary updates for one year
Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
MARKET LANDSCAPE
Impact of COVID-19 on CNS Therapeutics Market
The Cascading Effect of COVID-19 and Alzheimer’s Disease
Increased COVID-19 Morbidity and Mortality
Impact of COVID-19 Pandemic on Parkinson’s Disease and Movement Disorders
COVID-19 Isolation and Patients with Parkinson’s Disease
Special Role of Telemedicine During COVID-19 Pandemic
A Brief Overview on Impact of Covid-19 On Patients Suffering from Various Mental Disorders
Central Nervous System (CNS) Therapeutics: A Prelude
Global Central Nervous System Therapeutic Market Glimmers with Robust Health
List of FDA Approved CNS Drugs: 2018-2022
Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market
Patent Expiries of Leading CNS Drugs: 2008-2022
Developed Markets to Maintain their Dominance
Developing Market to Drive the Market Momentum, Asia-Pacific to Exhibit Fastest Growth
Neurodegenerative Disease & Mental Health: Lifeline Segments of CNS Therapeutics Market
CNS Cancer Segment to Post Fastest Growth
Competition
CNS Therapeutics – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Recent Market Activity
MARKET ANALYSIS BY THERAPEUTIC CATEGORY
Anti-Epilepsy Market
Disease Overview
Epilepsy Incidence by Type (2022E): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy
Symptomatic Epilepsy Incidence by Type (2022E): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy
Global Epilepsy Etiology: Percentage Breakdown by Type for 2022E
Drugs for Epilepsy
Market for Epilepsy Drugs
Regional Landscape
Developing Countries Struggle with Low Treatment Rates
High Unmet Needs Offer Scope for Market Growth
Treatment
Anti-Epileptic Drugs (AEDs) by Generic Name and Brand Names
Leading Anti-Epileptic Drugs
Leading Anti-Epileptic Drugs and Their Mechanism of Action
Patent Expiries of Major Anti-Epilepsy Drugs
FDA’s New Policy for AED Drugs to Bolster Market Growth
AAN Updated Guidelines on New AEDs Use for Treating New Onset Epilepsy (2019)
Select Currently Available Epilepsy Drugs
Innovative Drugs Needed for Better Treatment Compliance
Abounding Potential for NCEs
A New Research Demonstrates Effectiveness of Gluconate in Treating Neonatal Seizures
FDA Approves Epidiolex (Cannabidiol) – First Drug for Treating Dravet Syndrome and Lennox-Gastaut Syndrome
Refractory Childhood Epilepsy & Pregnancy Epilepsy – Major Concerns
Recent Approvals for Childhood Epilepsy
Review of Anti-Epilepsy Drugs
Anti-Alzheimer’s
Market Overview
Global Alzheimer’s Prevalence by Age Group
Alzheimer’s Phase III Completed Studies
Alzheimer’s Phase III Ongoing Studies
Treatment for Alzheimer’s
Select Leading Drugs for Alzheimer’s Disease by Drug Category
Patent Expiries of Leading Alzheimer’s Drugs
Alzheimer’s Drugs: A Market Plagued with Failures
Promising Compounds with Silver Lining
Updated FDA Standards Make Way for Increased Alzheimer’s Drug Testing
Rising Discontinuation of BACE Programs for Alzheimer’s to Dampen Market Growth
Rising Discontinuation of BACE Programs for Alzheimer’s to Dampen Market Growth
Elenbecestat’s Phase 3 Trials Halted
Novel Drug Delivery Method to the Brain Discovered
Alzheimer’s Association Provides Grant to Longeveron
A Review of Select Anti-Alzheimer’s Drugs
A Review of the Alzheimer’s disease
Alzheimer’s Effect on Brain
Causes for Alzheimer’s
Who Are at Risk?
Prevalence of Alzheimer’s Disease
Diagnosis of Alzheimer’s
Anti-Parkinson’s
Market Overview
Nourianz, An Add-on Medication for Treating Episodes of Parkinson’s Disease Secures FDA Approval
Recent Approvals
Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD
Xadago – Add-On Therapy for Parkinson’s Disease
NUPLAZID – The First and the Only Approved Drug for Psychosis related to Parkinson’s disease
Select Parkinson’s Phase III Completed Studies: As of June 2022
Select Parkinson’s Ongoing Phase III Studies: As of June 2022
Select Anti-Parkinson’s Drugs
Levodopa
Dopamine Agonists
Mirapex
GSK Discontinues Requip for PD and RSL Treatment
A Review of the Parkinson’s Disease
Anti-Depressants
Anti-Depressant Market: Percentage Share Breakdown by Depressive Disorder Type
Anti-Depressant Treatment
Select Antidepressants Drugs
Select Pipeline Drugs in Phase III for Depressive Disorders: As of June 2022
A Review of Depression
Prevalence of Depression
Causes of Depression
Types of Depressive Disorders
Available Treatment
Tricyclic Antidepressants
Monoamine Oxidase Inhibitors
Lithium Salts
Working of Antidepressants
Ranking of Antidepressants in Terms of Efficacy
Types of Antidepressants
NMDA Receptor Antagonists
NMDA Receptor (NMDAR)
NMDA Receptor Agonists
Acetylcholinesterase Inhibitors
Selective Serotonin Reuptake Inhibitors (SSRIs)
Workings of SSRIs
Safety Levels of SSRI Drugs
Adverse Effects of SSRI
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)
Other CNS Disorders (Multiple Sclerosis, Attention Deficit Hyperactivity Disorder (ADHD), and Insomnia)
Multiple Sclerosis (MS)
List of Approved Drugs for MS
Patent Expiration Date/Year of the Major MS Drugs
New Approvals
Novartis Receives FDA Approval for Mayzent for Use in Multiple Sclerosis
Mavenclad Gains FDA Approval
Celgene Files NDA for Ozanimod
Ocrevus – The First Approved Drug for Primary Progressive Multiple Sclerosis (PPMS)
Multiple Sclerosis: Pipeline Analysis
Select Pipeline Drugs in Phase III for Multiple Sclerosis: As of June 2022
A Review of Multiple Sclerosis (MS)
Types of Multiple Sclerosis
Clinical Subtypes of Multiple Sclerosis (MS)
Prevalence of MS
Causes of MS
Myths Surrounding Multiple Sclerosis
Symptoms of MS
Diagnosis of MS
Insomnia
Overview
List of Approved Drugs for Insomnia
Select Pipeline Drugs for Insomnia: As of June 2022
Zolpidem
Eszopiclone
A Review of Insomnia
Prevalence of Insomnia
Therapies for Insomnia
CNS Pain Management
Market Overview
Treatment
Drugs Indicated for Pain Management
Regional Overview
Players
Combination Therapies Gain Prominence
Key Trends in Chronic Pain Management
Neuropathic Pain Management: Market with High Potential
Select Phase III Ongoing Studies for Neuropathic Pain
Lyrica’s Generics Gain FDA Approval
Migraine Market: A Core Vertical in CNS Pain Management
Migraine Care: Select Patent Expiries (2013-2015)
Migraine Completed Phase III Studies
Migraine Ongoing Phase III Studies
Select Pain Management Drugs
Metabotropic Glutamate Receptors (mGluRs)
New Pain Management Drugs
Novartis Presents New Data for Aimovig
Reyvow, Eli Lilly’s Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
Three New Migraine Drugs Obtain FDA Approval
Eli Lilly’s Emgality Receives FDA Approval
An Insight into Mental Health Prevalence and Addressal
Global Prevalence of Mental Health Disorders by Type
Anti-Psychotics
FOCUS ON SELECT PLAYERS (Total 353 Featured)
Abbott Laboratories, Inc.
AbbVie, Inc.
Acumen Pharmaceuticals, Inc.
Alexza Pharmaceuticals
A. Menarini Industrie Farmaceutiche Riunite Srl
AC Immune SA
Addex Therapeutics
Ache Laboratorios Farmaceuticos SA
4D pharma plc
Acadia Pharmaceuticals, Inc.
AB Science SA
ABL Bio, Inc.
AcelRx Pharmaceuticals
Aarti Drugs Ltd.
Abion
For more information about this report visit https://www.researchandmarkets.com/r/f58kg0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets